Rufloxacin eyedrops: Effect of different formulations on ocular pharmacokinetics in rabbits

European Journal of Ophthalmology

Volumn 16, Issue 2, 2006, Pages 311-317

  Burgalassi, Susi ^a   Cappello, B ^b   Chetoni, P ^a   Iervolino, M ^b   Monti, D ^a   Saettone, M F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Hydroxypropyl cyclodextrin; Ocular pharmacokinetics; Rabbits; Rufloxacin base; Rufloxacin hydrochloride; Tamarind seed polysaccharide

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMPHOLYTE; EYE DROPS; POLYSACCHARIDE; RUFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PLANT SEED; PRIORITY JOURNAL; RABBIT; SUSPENSION; TAMARIND; VISCOSITY;

EID: 33745060781     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210601600219     Document Type: Article

References (31)

1. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs 2001; 61: 747-61.
2. Parks DJ, Abrams DA, Sarfaraji FA, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 1993; 115: 471-7.
3. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol 1995; 113: 1257-65.
4. Gangopadhyay N, Daniell M, Weih LA, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol 2000; 84: 378-84.
5. Donnenfeld ED, Schrier A, Perry HD, Aulicino T, Gombert ME, Snyder R. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology 1994; 101: 902-5.
6. Di Colo G, Burgalassi S, Chetoni P, Fiaschi MP, Zambito Y, Saettone MF. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 2001; 215: 101-11.
7. Fukuda M, Inoue A, Sasaki K, Takahashi N. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004; 48: 93-6.
8. Mattina R, Bonfiglio G, Cocuzza CE, Gulisano G, Cesana M, Imbimbo BP. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses. Chemotherapy 1991; 37: 389-97.
9. Mattina R, Cocuzza CE, Cesana M, Bonfiglio G. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemotherapy 1991; 37: 260-9.
10. Nucci P, Lombardo N, Cremonesi F, Manitto MP, Brancato R, Ghione M. Ocular pharmacokinetics of rufloxacin a new fluoroquinolone antibiotic. Clin Ter 1992; 140: 563-7.
11. Ghelardi E, Tavanti A, Davini P, et al. A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrob Agents Chemother 2004; 48: 3396-401.
12. Firestone BA, Dickason MA, Tran T. Solubility characteristics of three fluoroquinolone ophthalmic solutions in an in vitro tear model. Int J Pharm 1998; 164: 119-28.
13. Sortino S, Marconi G, Giuffrida S, De Guidi G, Monti S. Photophysical properties of rufloxacin in neutral aqueous solution. Photochem Photobiol 1999; 70: 731-6.
14. Cappello B, Iervolino M, Miro A, Chetoni P, Burgalassi S, Saettone MF. Formulation and preliminary in vivo testing of rufloxacin-cyclodextrin ophthalmic solutions. J Incl Phenom Macrocycl Chem 2002; 44: 173-6.
15. Burgalassi S, Chetoni P, Panichi L, Boldrini E, Saettone MF. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther 2000; 16: 497-509.
16. Burgalassi S, Raimondi L, Pirisino R, Banchelli G, Boldrini E, Saettone MF. Effect of xyloglucan (tamarind seed polysaccharide) on conjunctival cell adhesion to laminin and on corneal epithelium wound healing. Eur J Ophthalmol 2000; 10: 71-6.
17. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965; 4: 117-212.
18. Beck R, Keyserlingk J, Fisher U, Guthoff R, Drewelow B. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. Graefes Arch Clin Exp Ophthalmol 1991; 237: 89-92.
19. Gibaldi M, Perrier D. One-compartment model, and non-compartmental analysis based on statistical moment theory. In: Swarbrick J, ed. Pharmacokinetics. New York: M. Dekker, 1982; 1-111, 409-17.
20. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-58.
21. Longwell A, Birss S, Keller N, Moore D. Effect of topically applied pilocarpine on tear film pH. J Pharm Sci 1976; 65: 1654-7.
22. Chen FS, Maurice DN. The pH in the precorneal tear film and under a contact lens measured with a fluorescent probe. Exp Eye Res 1990; 50: 251-9.
23. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000; 27: 558-62.
24. Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999; 36: 59-79.
25. Davies NM, Wang G, Tucker IG. Evaluation of a hydrocortisone/ hydroxypropyl-β-cyclodextrin solution for ocular drug delivery. Int J Pharm 1997; 156: 201-9.
26. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Revs 1999; 36: 3-16.
27. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 1996; 37: 1199-203.
28. Fridriksdottir H, Loftsson T, Stefansson E. Formulation and testing of methazolamide cyclodextrin eye drop solutions. J Control Rel 1997; 44: 95-9.
29. Bary AR, Tucker IG, Davies NM. Considerations in the use of hydroxypropyl-β-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur J Pharm Biopharm 2000; 50: 237-44.
30. Wise R, Andrews JM, Matthews R, Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992; 29: 649-60.
31. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1966; 122: 1-17.